CGT Global Blog
CGT Global News
Stay ahead in the dynamic world of Accelerating Cell and Gene Therapy with the CGT Global blog and news page. Explore insightful articles, industry updates, product updates, and expert analysis on all things CGT Global. Stay informed, inspired, and connected with CGT Global – your go-to source for cutting-edge insights in the ever-evolving realm of research, clinical projects and healthcare.
T Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material
Introduction T cell activation is a foundational step in cell and gene therapy workflows, particularly in CAR T and other adoptive cell therapies. While much attention is placed on genetic engineering and manufacturing scale, activation is where functional outcomes begin to take shape. When done correctly, it enables strong expansion, optimal phenotypes, and durable responses. When done poorly, it can limit efficacy before a therapy even reaches the patient. What Is T Cell Activation? T cell activation is the process of stimulating…
Read More
Why CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies
Cell and gene therapy companies rely on several critical pieces of infrastructure to move therapies from development to clinical trials and ultimately to patient treatment. These include reliable sources of GMP compatible starting material, clinical trial support for complex cell therapy workflows, and hospitals capable of administering advanced therapies. Without these components in place, even the most promising therapies can face delays as developers work to coordinate donor collections, manufacturing inputs, and treatment sites. CGT Global supports therapy developers across this ecosystem…
Read More
Bulk CD34+ Isolation from Mobilized Leukopaks: GCSF vs GCSF + PLX vs PLX
Bulk CD34+ isolation is critical for stem cell therapy development, gene editing workflows, and advanced cell therapy research. When programs require large scale CD34+ recovery, the mobilization strategy used prior to leukapheresis directly impacts yield potential, scheduling timelines, and operational efficiency. Understanding the differences between GCSF mobilization, GCSF + PLX mobilization, and PLX only mobilization helps determine the optimal starting material for bulk CD34+ isolation. Bulk CD34+ Isolation from GCSF Mobilized Leukopaks GCSF mobilization is the most established and widely used strategy…
Read More
B Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons
Written by CGT Global B cell directed CAR T therapies are advancing quickly in autoimmune disease. As programs move beyond early trials, many teams discover that the hardest part is not engineering the cell. It is coordinating sourcing, QA, and patient delivery once timelines become real and unforgiving. In practice, B cell CAR T programs tend to break or slow down in the same places. Not because teams lack expertise, but because operational assumptions that work on paper rarely survive real world…
Read More
Blood Types Explained
What your blood type means and why it matters for donation and research Learn how ABO and Rh blood types work, how common each type is, and why donors are essential for lifesaving care and medical research. CGT Global donors are compensated from $25 and up to $1,000 for your time and effort depending on your donation type. Donor Compensation What Your Blood Type Means and Why It Matters for Cell Isolation and Research Learn how ABO and Rh blood types work,…
Read More
From Donor Recall to Data Integrity: The Operational Backbone of Ex Vivo Cell Therapy
By Eliona Kola, Process Development Scientist “Hey Sophie, will the lab receive the leukopak from the recall donor tomorrow for the CD3⁺ isolations?” That’s a question we ask our Director of Logistics Operations who also leads our Donor Scheduling Department more often than not. Coordinating around a donor’s availability can be challenging for any team, but Sophia and her team understand just how critical donor recallability is, especially in ex vivo cell therapy. In this blog, I’ll highlight the importance of ex…
Read More
Everything CGT Global Offers: Starting Materials, Isolated Cells, and Clinical Grade Supply
1. Leukopaks (RUO, Mobilized, Clinical, and GMP Aligned) Leukopaks remain one of the most common upstream inputs for immune cell workflows. We support formats that match how cell therapy teams actually operate. RUO leukopaks Fresh and cryopreserved options for discovery, preclinical, and process development. Mobilized leukopaks Mobilized options for programs requiring higher progenitor content or mobilized immune starting material. Clinical and GMP aligned leukopakshttps://cgt.global/human-blood-products/mobilized-peripheral-blood/mobilized-peripheral-blood-leukopaks/ Fresh and cryopreserved clinical grade options designed for teams moving toward trials and manufacturing scale. If you are…
Read More
Cryopreserved Leukopak Viability and Supplier Selection
What to Expect Post Thaw and How to Choose a GMP Partner Cryopreserved leukopaks are getting adopted fast for one simple reason. Fresh starting material creates supply chain risk. Leukopak deliveries can be late, arrive outside temperature requirements, or miss a critical manufacturing window entirely. When that happens, teams do not just lose a leukopak. They lose staff time, reagents, a manufacturing slot, and sometimes patient scheduling flexibility. Cryopreservation is one of the most practical ways to remove many of those failure…
Read More
GMP Leukopak Partner Guide for Clinical Development
Plus a Fresh vs Cryopreserved Decision Guide for Allogeneic Programs If you are building a cell therapy program, your starting material is not a minor detail. It is one of the biggest drivers of downstream consistency, cost, and timeline risk. That is why the GMP leukopak has become a cornerstone input for teams moving from discovery into clinical development. In plain terms, a GMP leukopak is a concentrated collection of white blood cells that is collected, handled, tested, and documented under Good…
Read More
Advancing CAR NK Therapy: Why Leukopak Quality and Donor Characterization Matter
CAR NK therapy is gaining traction as a next wave cell therapy platform. Compared to CAR T, CAR NK programs offer the potential for allogeneic manufacturing, improved safety profiles, and scalable off the shelf products. But CAR NK workflows are less forgiving when it comes to starting material. NK cells are more sensitive to collection conditions, handling, and donor variability. That makes leukopak quality and donor characterization critical inputs for consistent NK cell isolation and expansion. If those inputs are not controlled,…
Read More
Fresh vs Cryopreserved Leukopaks for T Cell Expansion and CAR T Manufacturing
Why the fresh vs cryo decision matters Most CAR T processes are built around predictable inputs. When those inputs shift, it becomes harder to hit target yields, expansion timing, and manufacturing release criteria. Fresh and cryopreserved leukopaks differ in: logistics and scheduling flexibility post processing recovery and expansion behavior sensitivity to handling variables lot to lot consistency Choosing the right format is not about “which is better.” It is about what your process and program stage require. Fresh leukopaks Best for workflows…
Read More
Armored CAR T
Strengthening T Cells for the Toughest Tumors CAR T therapy changed what is possible in blood cancers. But solid tumors remain one of the toughest frontiers in oncology. Not because we do not know what to target.Because the tumor environment fights back. Solid tumors suppress immune activity, block infiltration, and exhaust T cells before they can finish the job. That is why the next chapter of CAR T is not only about recognition. It is about survival, persistence, and control inside hostile…
Read More